Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer Inc       

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Ranbaxy Had Smaller Recall of Generic Lipitor in August Over Pill Mix-up

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/29/2012 | 06:27pm CEST
   By Peter Loftus 
 

Ranbaxy Laboratories Ltd. (500359.BY) recalled more than 32,000 bottles of its generic version of cholesterol-lowering drug Lipitor over a potential pill mix-up in August--nearly three months before a larger recall for the presence of small glass particles in some bottles.

The retail-level recall in August was triggered by a pharmacist's discovery of a 20-milligram tablet of atorvastatin--the generic name for Lipitor--inside a sealed bottle of 10-mg atorvastatin, according to details posted online this week by the U.S. Food and Drug Administration.

In an August letter to customers initiating the voluntary recall of one product lot, Ranbaxy said it couldn't rule out the possibility that the pill mix-up occurred at its facility.

The FDA has now designated the August recall as Class 2, which is reserved for situations when use of a drug may cause temporary or medically reversible health problems, or where the probability of serious adverse events is remote.

The lot recalled in August was Ranbaxy's 10-mg, 90-count tablets, with lot number 2407258 and an expiration date May 2014, according to the FDA.

Ranbaxy spokesmen couldn't immediately be reached Thursday.

The mixed-pill recall preceded a separate, larger Ranbaxy recall earlier in November of 41 lots of its generic atorvastatin, because some may have contained tiny glass particles resembling fine grains of sand. Neither Ranbaxy nor the FDA have said how many bottles in total were recalled in the latest action.

Ranbaxy, which holds more than 40% of the U.S. market for atorvastatin prescriptions, said in a press release Wednesday the probability of an adverse health event due to consumption of the tablets recalled for potential glass particles is unlikely, but can't be ruled out.

Ranbaxy said it hadn't received any reports of adverse events related to the more recent recall. The affected lot numbers in the more recent recall can be found here: http://ranbaxyusa.com/newsdisp281112.aspx.

The FDA said in a statement Thursday Ranbaxy has stopped manufacturing atorvastatin until it has investigated the cause of the glass particles and fixed the problem. The FDA said it doesn't anticipate a shortage because generic Lipitor is available from several manufacturers. But the agency is monitoring the situation and is working with other manufacturers to ensure adequate supply.

Ranbaxy was one of the first companies to begin selling generic Lipitor in the U.S. a year ago, after Pfizer Inc. (>> Pfizer Inc.) lost market exclusivity for the branded version of the drug. Pfizer's Lipitor was once the best-selling drug in the world, but sales have plummeted as it lost market share to multiple generic alternatives.

Write to Peter Loftus at peter.loftus@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER INC
03:10p PFIZER : can`t complain about execution drug
07/26 LEGISLATOR : Pfizer can't complain about execution drug
07/26 SPARK THERAPEUTICS : and Pfizer Announce Updated Data from First Cohort in Hemop..
07/26 PFIZER : Global Citizen and Pfizer - Convention
07/26 Exclusive - Teva, Mylan eye Pfizer's Brazil venture, sources say
07/25 APNEWSBREAK : Pfizer: Arkansas execution would 'misuse' drug
07/24 PFIZER : Labour proposes scrapping £1bn tax relief for innovation
07/23 SPARK THERAPEUTICS : and Pfizer Announce Receipt of FDA Breakthrough Therapy Des..
07/22 PFIZER : Lasco Distributors Limited and Medimpex Jamaica Limited to face Pfizer ..
07/22 PFIZER : Global Citizen and Pfizer - Convention
More news
Sector news : Pharmaceuticals - NEC
03:02pDJBAYER : Reports Higher Second-Quarter Profit, Raises Guidance -- 2nd Update
02:33pDJGLAXOSMITHKLINE : Glaxo Swings to Loss on Write-Down But Core Earnings, Revenue ..
02:06pDJELI LILLY : CEO to Retire
02:06pDJGLAXOSMITHKLINE : Swings to Loss
02:02pDJELI LILLY : CEO Lechleiter to Retire, Ricks to Replace Him
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2015 Update
2015 Antibiotics Stocks To Benefit From 21st Century Cures Act
2015 ISIS PHARMA STOCK DROPS ON GOOD NEWS : Re-Evaluating The Bull Case
2015 DOW DOGS : 14.63% More Returns From 5 Lowest Priced As Of August 6 Per indexArb
2015 Pfizer's GL-2045 an Orphan Drug for CIDP
Advertisement
Financials ($)
Sales 2016 52 635 M
EBIT 2016 19 322 M
Net income 2016 11 550 M
Debt 2016 17 470 M
Yield 2016 3,23%
P/E ratio 2016 20,62
P/E ratio 2017 17,15
EV / Sales 2016 4,58x
EV / Sales 2017 4,40x
Capitalization 223 368 M
More Financials
Chart PFIZER INC
Duration : Period :
Pfizer Inc Technical Analysis Chart | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 39,1 $
Spread / Average Target 6,1%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
Mikael Dolsten President-Worldwide Research & Development
W. Don Cornwell Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC13.96%223 368
JOHNSON & JOHNSON21.84%344 243
PFIZER INC.14.10%223 368
NOVARTIS AG-5.30%219 971
ROCHE HOLDING LTD.-9.99%218 902
MERCK & CO., INC.10.49%161 542
More Results